Armata Pharmaceuticals Inc. buy stratec
Summary
This prediction ended on 09.11.18 with a price of €3.47. Massive losses of -75.20% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Armata Pharmaceuticals Inc. | -5.556% | -5.556% | 93.496% | -27.879% |
iShares Core DAX® | -0.051% | 4.829% | 17.062% | 18.811% |
iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% | 56.555% |
iShares Nikkei 225® | 0.658% | -2.173% | 13.159% | 7.768% |
iShares S&P 500 | 0.964% | 2.547% | 30.492% | 47.355% |
Comments by stratec for this prediction
In the thread Armata Pharmaceuticals Inc. diskutieren
APHB with a large market opportunities being addressed
The company started the year off on the right foot when it announced top lin e data for the first seven patients treated under its ongoing single-patient expanded access program (administering lead drug candidates AB-SA01 for Staphylococcus aureus infections and AB-PA01 for Pseudomonas aeruginosa
infections). All of these patients were severely ill and not responding to treatment with antibiotics when they were enrolled in the study, so in other words, this expanded access approach was a last-ditch effort to save their lives.
In March, the company presented in vivo preclinical data revealing that AB-PA01 reduces biofilm in a Pseudomonas aeruginosa preclinical model, which further supports its potential for efficacy, as this has been an obstacle for previous treatments. This is yet another factor suggesting the potential of bacteriophage therapeutics to change the treatment landscape.